In This Story
Arvinas Inc. (ARVN-3.21%) has submitted its Form 10-K filing for the fiscal year ended December 31, 2024.
The filing details Arvinas' focus on developing PROTAC protein degraders, with key programs including vepdegestrant for ER+/HER2- breast cancer, ARV-393 for non-Hodgkin Lymphoma, and ARV-102 for neurodegenerative diseases.
Arvinas reported net losses of $198.9 million for 2024, with an accumulated deficit of $1,531.6 million. The company anticipates continued losses as it advances its clinical programs.
The company highlighted its collaboration with Pfizer for the development and commercialization of vepdegestrant, sharing development costs and potential revenues.
Arvinas has entered into an agreement with Novartis for the development of luxdegalutamide (ARV-766), receiving an upfront payment and potential milestone payments.
The filing outlines the company's strategy to expand its pipeline, focusing on oncology and neuroscience, and leveraging its PROTAC Discovery Engine.
Arvinas identified risks including dependency on third-party manufacturers, competition from other biotechnology companies, and the need for substantial additional funding.
The company is actively pursuing additional collaborations and licenses to support its research and development efforts.
Arvinas continues to invest in its intellectual property portfolio, with numerous patents issued and pending globally.
The filing also discusses regulatory challenges, including the need for FDA approval and potential changes in regulatory policies that could impact development timelines.
This content was summarized by generative artificial intelligence using public filings retrieved from SEC.gov. The original data was derived from the Arvinas Inc. annual 10-K report dated February 11, 2025. To report an error, please email earnings@qz.com.